Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
58 Results for "
mTORC1 activity
" in MedChemExpress (MCE) Product Catalog:
Products (58)
58 Results for "mTORC1 activity" in MCE Product Catalog:
Cat. No.: HY-10219R
CAS No.: 53123-88-9
Synonyms: Sirolimus (Standard); AY-22989 (Standard); NSC 226080 (Standard)
PQR530 is a potent, ATP-competitive, orally bioavailable and brain-penetrant dual pan-PI3K/mTORC1/2 inhibitor, with a subnanomolar Kd toward PI3Kα and mTOR (0.84 and 0.33 nM, respectively). Antitumor activity .
Target:
Leu-AMS (compound 6), a leucine analogue, is a potent inhibitor of leucyl-tRNA synthetase (LRS) with an IC50 of 22.34 nM, which inhibits the catalytic activity of LRS but did not affect the leucine-induced mTORC1 activation. Leu-AMS shows cytotoxicity in cancer cells and normal cells, and inhibits the growth of bacteria .
Synonyms: Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)
Cat. No.: HY-10219S1
Purity: 97.05%
Synonyms: Sirolimus-13C,d3; AY-22989-13C,d3 NSC 226080-13C,d3
Cat. No.: HY-N2517
CAS No.: 15266-35-0
Category:
Rutaceae Extract Alkaloids Evodia rutaecarpa (Juss.) Benth. Quinoline Alkaloids Plants Disease Research Fields Cancer
Target:
Cat. No.: HY-W266188
CAS No.: 84600-66-8
Cat. No.: HY-134922
CAS No.: 181373-35-3
Synonyms: REDD1 inducer-1
Target:
Research Areas:
NS1-IN-1 (REDD1 inducer-1) is a naphthalimide compound and an NS1 inhibitor. NS1-IN-1 antagonizes influenza A virus NS1-mediated inhibition of host gene expression and induces REDD1 expression. NS1-IN-1 suppresses the mTORC1 signaling pathway via a TSC1-TSC2 dependent mechanism. NS1-IN-1 exhibits broad antiviral activity against influenza virus and vesicular stomatitis virus (VSV), with low toxicity .
Cat. No.: HY-17654
CAS No.: 1429497-30-2
BIEGi-1 is an EGFR inhibitor. BIEGi-1 effectively disrupts the EGFR-Rheb interaction in cells. BIEGi-1 robustly inhibits EGFR kinase activity (reduces p-Y1068-EGFR) as well as mTORC1 activation (reduces p-T389-S6K1) in EGFR-mutant cells. BIEGi-1 shows strong antiproliferative effects on EGFR-mutant PC9 and HCC827 cells with IC50 values of 17 nM and 20 nM, respectively. BIEGi-1 can be used for the study of cancers harboring EGFR mutations, such as non-small cell lung cancer (NSCLC) .
Cat. No.: HY-170670
CAS No.: 2027551-01-3
DQ661 is a potent PPT1 inhibitor. DQ661 is a dimeric quinacrine autophagy inhibitor. DQ661 inhibits mTORC1 activity. DQ661 decreases the protein expression of pS6K T389, pS6 S240-244. DQ661 shows anticancer activity .
Cat. No.: HY-15113A
CAS No.: 143984-17-2
Target:
Research Areas:
Y-29794 tosylate is a selective, orally active inhibitor for non-peptide prolyl endopeptidase (PREP), with an IC50 of 3 nM and a Ki of 0.95 nM. Y-29794 tosylate enhances the effect of thyrotropin-releasing hormone (TRH) on the release of ACh in the rat hippocampus, exhibits potential neuroprotective efficacy. Y-29794 tosylate exhibits anticancer activity through inhibition of the IRS1-AKT-mTORC1 pathway. Y-29794 tosylate penetrates the brain-blood barrier (BBB) .
Cat. No.: HY-118160
CAS No.: 65240-86-0
Synonyms: NSC 73233
Target:
NO Synthase Drug Derivative IKK NF-κB HDAC Reactive Oxygen Species (ROS) AMPK mTOR PI3K Akt Autophagy Apoptosis
Research Areas:
Cardiovascular Disease Infection Neurological Disease Inflammation/Immunology Cancer
PPM-18 (NSC 73233) is a Vitamin K (HY-B2172) analog. PPM-18 prevents LPS-induced IκBα degradation, thereby inhibiting NF-κB activation and nuclear translocation of NF-κB. PPM-18 inhibits LPS-induced nitrite production and iNOS expression. PPM-18 inhibits HDAC6. PPM-18 induces ROS accumulation, activates AMPK, inhibits the mTORC1 and PI3K/AKT pathways, initiates Autophagy, and induces Apoptosis. PPM-18 suppresses seizures in zebrafish and mouse epilepsy models. PPM-18 prevents LPS-induced lethal toxicity and delayed hypotension. PPM-18 exhibits anticancer activity against leukemia and bladder cancer. PPM-18 can be used in research related to septic shock, bladder cancer and atherosclerosis .
Cat. No.: HY-155542
CAS No.: 3049676-15-2
RORγ antagonist 1 (compound 22), a potent betulinic acid derivative, is an antagonist of RORγ (KD=0.18 μM). RORγ antagonist 1 exhibits anti-proliferative activity in HPAF-II pancreatic cancer xenograft model. RORγ antagonist 1 inhibits RAS/MAPK and AKT/mTORC1 pathway, and induces caspase-dependent apoptosis in pancreatic cancer cells .
CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo .
Cat. No.: HY-N3628
CAS No.: 119188-33-9
Target:
Cat. No.: HY-13328R
CAS No.: 1224844-38-5
Synonyms: INK-128 (Standard); MLN0128 (Standard); TAK-228 (Standard)
Sapanisertib (INK-128; MLN0128; TAK-228) Standard is the analytical standard of Sapanisertib (HY-13328). This product is intended for research and analytical applications. Sapanisertib (INK-128; MLN0128; TAK-228) is an orally active dual mTORC1/mTORC2 inhibitor. Sapanisertib directly and simultaneously inhibits mTORC1/2 activity through competitive binding with ATP, thereby comprehensively blocking downstream processes such as protein and lipid synthesis and cytoskeletal reorganization, consequently suppressing tumor cell proliferation and promoting apoptosis. Sapanisertib is applicable to research on melanoma, ovarian cancer, pulmonary fibrosis, and hematological malignancies .
Cat. No.: HY-N0656AR
CAS No.: 7562-61-0
Target:
Cat. No.: HY-15113
CAS No.: 129184-48-1
Target:
Research Areas:
Y-29794 is a selective, orally active inhibitor for non-peptide prolyl endopeptidase (PREP), with an IC50 of 3 nM and a Ki of 0.95 nM. Y-29794 enhances the effect of thyrotropin-releasing hormone (TRH) on the release of ACh in the rat hippocampus, exhibits potential neuroprotective efficacy. Y-29794 exhibits anticancer activity through inhibition of the IRS1-AKT-mTORC1 pathway. Y-29794 penetrates the brain-blood barrier (BBB) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
